SCHEMBL21554546

SCHEMBL21554546

CC(C)(C)OC(=O)Cc1ccc(CC(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.50
CAMK2A Q9UQM7 1/20 0.50
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49
RXRG P48443 1/20 0.49
AKR1B1 P15121 1/20 0.48
ALDH1A1 P00352 3/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GAA P10253 3/20 0.47
TSHR P16473 2/20 0.47
PTGS1 P23219 2/20 0.47
ABCC4 O15439 1/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
MTNR1A P48039 1/20 0.47
MTNR1B P49286 1/20 0.47
KLKB1 P03952 1/20 0.44
CTSB P07858 1/20 0.44
NR1H4 Q96RI1 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1346095 0.86 TSHR (0.56) AKR1B1ALDH1A1TSHRMTNR1AMTNR1B
SCHEMBL9077714 0.86 ALDH1A1 (0.50) CA2CAMK2ARXRARXRBRXRG
SCHEMBL4745549 0.85 ALDH1A1 (0.50) RXRARXRBRXRGALDH1A1GAA
SCHEMBL19085086 0.85 MTNR1A (0.47) ALDH1A1HPGDLMNAMTNR1AMTNR1B
SCHEMBL7517689 0.85 HPGD (0.50) HPGDMTNR1AMTNR1BTDP1
SCHEMBL1283948 0.85 CA2 (0.50) CA2CAMK2ALMNAMTNR1AMTNR1B
SCHEMBL12697638 0.83 PLA2G4B (0.56) RXRARXRBRXRGPTGS1NR1H4
SCHEMBL5866843 0.83 LOXL2 (0.46) ALDH1A1LMNAMTNR1AMTNR1BKDM4E
SCHEMBL479237 0.83 MTNR1A (0.46) ALDH1A1GAALMNAMTNR1AMTNR1B
SCHEMBL21880654 0.83 MTNR1A (0.46) TSHRLMNAMTNR1AMTNR1BPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11541051-B2 Compositions and methods for treating CDK4/6-mediated cancer ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-01-03 US disclosed
US-20190336503-A1 COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2019-11-07 US disclosed
US-20120142706-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK SHARP & DOHME LLC 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190336503-A1 COMPOSITIONS AND METHODS FOR TREATING CDK4/6-MEDIATED CANCER CDK4, CDK6, CDK2 CA2 4250/4885CAMK2A 1892/4885RXRA 2633/4885
US-11541051-B2 Compositions and methods for treating CDK4/6-mediated cancer CDK4, CDK6, CDK2 CA2 4250/4885CAMK2A 1892/4885RXRA 2633/4885
US-20120142706-A1 SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT GPR119, GPR27, GCGR CA2 1216/4885CAMK2A 1294/4885RXRA 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.